AR036276A1 - Uso de un compuesto 15-ceto-prostaglandina para el tratamiento de hipertension ocular y glaucoma - Google Patents

Uso de un compuesto 15-ceto-prostaglandina para el tratamiento de hipertension ocular y glaucoma

Info

Publication number
AR036276A1
AR036276A1 ARP020103150A ARP020103150A AR036276A1 AR 036276 A1 AR036276 A1 AR 036276A1 AR P020103150 A ARP020103150 A AR P020103150A AR P020103150 A ARP020103150 A AR P020103150A AR 036276 A1 AR036276 A1 AR 036276A1
Authority
AR
Argentina
Prior art keywords
glaucoma
compound
prostaglandine
ceto
treatment
Prior art date
Application number
ARP020103150A
Other languages
English (en)
Spanish (es)
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of AR036276A1 publication Critical patent/AR036276A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ARP020103150A 2001-08-23 2002-08-22 Uso de un compuesto 15-ceto-prostaglandina para el tratamiento de hipertension ocular y glaucoma AR036276A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31411001P 2001-08-23 2001-08-23

Publications (1)

Publication Number Publication Date
AR036276A1 true AR036276A1 (es) 2004-08-25

Family

ID=23218598

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020103150A AR036276A1 (es) 2001-08-23 2002-08-22 Uso de un compuesto 15-ceto-prostaglandina para el tratamiento de hipertension ocular y glaucoma

Country Status (12)

Country Link
US (1) US20030060511A1 (enExample)
EP (1) EP1420793A1 (enExample)
JP (1) JP2004521960A (enExample)
KR (1) KR20040029012A (enExample)
CN (1) CN1575178A (enExample)
AR (1) AR036276A1 (enExample)
BR (1) BR0205932A (enExample)
CA (1) CA2458230A1 (enExample)
MX (1) MXPA04001604A (enExample)
NO (1) NO20031779D0 (enExample)
WO (1) WO2003018025A1 (enExample)
ZA (1) ZA200302911B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082257A2 (en) * 2002-03-28 2003-10-09 Sucampo Ag Method for treating ocular hypertension and glaucoma
AR043161A1 (es) * 2003-02-14 2005-07-20 Sucampo Pharmaceuticals Inc Composicion oftalmica para tratar hipertension ocular y glaucoma
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
WO2012137987A1 (en) * 2011-04-07 2012-10-11 Sucampo Ag Method for treating asthenopia

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932389A (en) * 1974-12-11 1976-01-13 Pfizer Inc. 2-Descarboxy-2-(tetrazol-5-yl)-11-desoxy-15-substituted-.omega.-pentanorprostaglandins
US5212200A (en) * 1987-09-18 1993-05-18 R-Tech Ueno, Ltd. Ocular hypotensive agents
US5296504A (en) * 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
EP0569046B1 (en) * 1988-09-06 2002-11-13 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6187813B1 (en) * 1990-04-10 2001-02-13 Pharmacia & Upjohn Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
ATE162074T1 (de) * 1988-10-01 1998-01-15 R Tech Ueno Ltd Oculare hypotensive mittel
US5194429A (en) * 1988-10-01 1993-03-16 K.K. Ueno Seiyaku Oyo Kenkyujo Ocular hypotensive agents
TW249226B (enExample) * 1990-04-04 1995-06-11 Aderk Ueno Kk
US5208256A (en) * 1990-05-22 1993-05-04 R-Tech Ueno, Ltd. Treatment of ocular hypertension with a synergistic combination for ocular administration
CA2046069C (en) * 1990-07-10 2002-04-09 Ryuji Ueno Treatment of inflammatory diseases with 15-keto-prostaglandin compounds
AU687906B2 (en) * 1993-12-15 1998-03-05 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
TW420611B (en) * 1995-03-10 2001-02-01 R Tech Ueno Ltd Pharmaceutical composition containing prostanoic acid compounds for the treatment of optic nerve disorder
AU7680096A (en) * 1995-12-22 1997-07-17 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
US6458836B1 (en) * 2000-03-16 2002-10-01 Sucampo, A.G. Treatment of ocular hypertension and glaucoma
US20020035148A1 (en) * 2000-07-20 2002-03-21 Ryuji Ueno Treatment of ocular hypertension

Also Published As

Publication number Publication date
CA2458230A1 (en) 2003-03-06
WO2003018025A1 (en) 2003-03-06
NO20031779L (no) 2003-04-22
MXPA04001604A (es) 2004-07-08
CN1575178A (zh) 2005-02-02
EP1420793A1 (en) 2004-05-26
JP2004521960A (ja) 2004-07-22
NO20031779D0 (no) 2003-04-22
US20030060511A1 (en) 2003-03-27
KR20040029012A (ko) 2004-04-03
BR0205932A (pt) 2004-02-17
ZA200302911B (en) 2003-10-14

Similar Documents

Publication Publication Date Title
AR039130A2 (es) Metodo de administracion de un agente farmaceuticamente activo a un ojo humano
CO6351718A2 (es) Suministro de liberacion sostenida de agentes activos para tratar glaucoma e hipertension ocular
AR039131A2 (es) Metodo para administrar un agente farmaceuticamente activo a un tejido a ser tratado en un cuerpo y metodo para administrar un agente farmaceuticamente activo a un ojo
DK1385452T3 (da) Anordning til tilförsel af et ophthalmisk medikament
UY28709A1 (es) Derivados de prostaglandinas
ATE493981T1 (de) Einmal tägliche dosierformen von trospium
BR0302584A (pt) Combinação de brimonidina e timolol para uso oftálmico tópico
ECSP034815A (es) "composiciones de timolol y de lipido hipotensivas y los metodos para utilizarlas"
ES2189002T3 (es) Procedimiento in vitro y utilizacion de composiciones farmaceuticas para el tratamiento de celulas ciliares del oido interno.
Ferris Results of 20 years of research on the treatment of diabetic retinopathy
ATE420624T1 (de) Pharmazeutische zusammensetzungen zurbehandlung von augenerkrankungen
AR035541A1 (es) Un metodo de tratamiento para pacientes que sufren de glaucoma severo o necesitan una reduccion de la presion intraocular (pio) y el uso de una combinacion de agentes reductores de la pio
BRPI0509220A (pt) método, formulação oftálmica e kit para para o tratamento de olho ressecado moderno a grave; método para o tratamento de olho ressecado crÈnico; e métodos para reduzir a vermelhidão e a produção de citocinas inflamatórias por células no epitélio
AR036276A1 (es) Uso de un compuesto 15-ceto-prostaglandina para el tratamiento de hipertension ocular y glaucoma
AR031288A1 (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas
BR0214196A (pt) Método e composição para reduzir a atividade de inibir o crescimento de uma célula cancerosa, para tratar de paciente com câncer
ITRM20010438A1 (it) Preparato oftalmico a base di n-acetilcisteina per il trattamento della sindrome dell'occhio secco.
DK1621207T3 (da) Mixture of defibrotide and G-CSF, and its use for activating haematopoietic progenitors
AR033207A1 (es) Metodo de tratamiento de desordenes inflamatorios oculares y de desordenes relacionados con angiogenesis del segmento posterior del ojo usando un derivado amida de flurbiprofen o ketorolac
BR0209601A (pt) Método para o tratamento da hipertensão ocular e do glaucoma
ES2181915T3 (es) Ctla-8 en combinacionpn con g-csf y il-6, y uso de ctla-8 para tratar infecciones.
BR0211545A (pt) Método e composição para tratamento de hipertensão ocular e glaucoma
IT1305294B1 (it) Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari.
AR045766A1 (es) Procedimiento mejorado de tratamiento de trastornos del crecimiento
Makimoto et al. Long-term effect of topically applied isopropyl unoprostone on microcirculation in the choroid-retina

Legal Events

Date Code Title Description
FB Suspension of granting procedure